Argenica Therapeutics (ASX:AGN) Ending Cash Position : A$8.43 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Ending Cash Position?

Argenica Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was A$8.43 Mil.

Argenica Therapeutics's quarterly Ending Cash Position increased from Dec. 2022 (A$8.13 Mil) to Jun. 2023 (A$9.29 Mil) but then declined from Jun. 2023 (A$9.29 Mil) to Dec. 2023 (A$8.43 Mil).

Argenica Therapeutics's annual Ending Cash Position increased from Jun. 2021 (A$7.14 Mil) to Jun. 2022 (A$8.91 Mil) and increased from Jun. 2022 (A$8.91 Mil) to Jun. 2023 (A$9.29 Mil).

Argenica Therapeutics Ending Cash Position Historical Data

The historical data trend for Argenica Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Ending Cash Position Chart

Argenica Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Ending Cash Position

7.14

8.91

9.29

Argenica Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial			5.31	8.91	8.13	9.29	8.43

Argenica Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Argenica Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	8.914	+	0.375
	=	9.29

Argenica Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	9.289	+	-0.861
	=	8.43

Argenica Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Argenica Therapeutics (ASX:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

117 Broadway, Unit 4, Nedlands, WA, AUS, 6009

Website

https://www.argenica.com.au

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines